Understanding the role of Gut Immune dysfunction and Gut Microbiome in pathogenesis of Central Nervous System co-morbidities in people living with HIV (R21 Clinical Trial Not Allowed) | RFA MH 22 230

Frequently Asked Questions (FAQs)

What is the title of this NIH funding opportunity?

The opportunity is titled "Understanding the role of Gut Immune dysfunction and Gut Microbiome in pathogenesis of Central Nervous System co-morbidities in people living with HIV (R21 Clinical Trial Not Allowed)."

What are the Funding Opportunity Number and CFDA number?

The Funding Opportunity Number is RFA-MH-22-230 and the CFDA number is 93.242.

What type of grant mechanism is this?

This is an NIH R21 mechanism, which is typically intended for exploratory, early-stage, or high-impact projects that generate foundational data, test novel concepts, or open up new research directions (rather than supporting large, definitive programs).

Are clinical trials allowed under this announcement?

No. This opportunity is explicitly labeled "Clinical Trial Not Allowed," meaning applicants should not propose studies that prospectively assign human participants to interventions in order to evaluate health-related outcomes.

If clinical trials are not allowed, can the project still involve human participants?

Yes, human-focused research may still be possible if it stays within non-trial parameters. The description notes that observational or mechanistic clinical research may be acceptable, but proposals need to be framed carefully to remain compliant with the "clinical trial not allowed" requirement.

What is the main scientific focus of this funding opportunity?

The focus is the gut-brain axis in the context of HIV, specifically how HIV-associated changes in the gut microbiota and gut immune function contribute to central nervous system (CNS) comorbidities and mental health outcomes in people living with HIV.

Is the program looking for correlational studies or mechanistic studies?

The emphasis is on uncovering mechanisms, not just correlations. Projects should aim to explain how HIV infection and/or antiretroviral therapy (ART) disrupt gut microbial communities and gut mucosal immunity, how those disruptions affect immune signaling and inflammation, and how downstream pathways influence brain biology.

What kinds of CNS outcomes or comorbidities are relevant to this opportunity?

The opportunity highlights CNS comorbidities and mental health outcomes in people living with HIV, including examples such as depression, anxiety, cognitive impairment, and other CNS-related comorbidities occurring alongside HIV.

What neurobiological topics does the announcement specifically call out?

The announcement explicitly highlights brain functions, neural circuits, neurotransmitters, signaling pathways, and synaptic plasticity as areas of interest.

How does antiretroviral therapy (ART) fit into the research scope?

The scope includes understanding how HIV infection and/or ART may disrupt the gut microbial community and gut mucosal immunity, and how those effects may propagate through immune and metabolic routes to alter CNS signaling and plasticity in the setting of ART exposure.

What types of studies are supported (basic vs. clinical)?

The opportunity supports both basic and clinical mechanistic studies, as long as they remain compliant with the non-clinical-trial constraint.

What might a basic mechanistic study look like under this announcement?

Basic studies might use model systems to isolate causal pathways linking microbiome shifts or gut immune activation to neural and behavioral phenotypes relevant to HIV.

What might a clinical mechanistic study look like under this announcement?

Clinical mechanistic studies might involve profiling and integrative analyses in people living with HIV that examine microbiome composition and function, markers of gut barrier integrity, immune activation and inflammatory mediators, and neurocognitive or neuropsychiatric measures, with an emphasis on identifying biological pathways connecting these domains.

What does "move beyond describing changes exist" mean in practice for applicants?

It means the project should go further than reporting that differences in the microbiome, immune markers, or CNS outcomes are present. The application should aim to clarify how gut immune dysfunction and microbiome alterations can drive downstream immune, inflammatory, metabolic, and neurobiological changes that plausibly contribute to CNS comorbidities in people living with HIV.

What types of organizations are eligible to apply?

A wide range of applicants are eligible, including: state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; non-federally recognized Native American tribal organizations; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding institutions of higher education); for-profit organizations other than small businesses; small businesses; and other organizations.

Are community-based or faith-based organizations eligible?

Yes. The opportunity explicitly includes faith-based or community-based organizations among eligible applicant types.

Are minority-serving institutions specifically mentioned as eligible?

Yes. The listing calls out Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).

Can federal agencies apply?

Yes. Eligible applicants include eligible federal agencies.

Are U.S. territories or possessions eligible to apply?

Yes. The eligibility list includes U.S. territories or possessions.

Are non-U.S. (foreign) organizations eligible?

Yes. The opportunity notes that non-U.S. entities (foreign organizations) are eligible.

When was this funding opportunity created?

The opportunity was created on April 25, 2022.

What was the original closing date listed for this opportunity?

The original closing date listed is November 18, 2022.

Does the provided information include an award ceiling or expected number of awards?

No. The excerpt does not provide an award ceiling or the expected number of awards.

What does the R21 format imply about project scope and budget?

Based on the description provided, the R21 format typically implies smaller, time-limited exploratory budgets compared to larger R-series grants. Applicants are generally expected to propose sharply focused aims that can be accomplished within that scope.

What is the longer-term goal or implication of the research supported by this program?

The program is designed to accelerate mechanistic understanding of how HIV and ART-related disruptions in the gut microbiome and gut immune environment may shape CNS biology and mental health. Over the long term, clearer mechanisms could point to future targets for prevention or treatment strategies, even though intervention trials are not part of this specific call.

What is a key compliance pitfall applicants should watch for?

A key boundary is the "clinical trial not allowed" requirement. Applications should avoid proposing studies that prospectively assign participants to interventions to evaluate health-related outcomes, and should frame any human research as observational or mechanistic work that stays within non-trial parameters.